AOP Orphan Pharmaceuticals announces progress of Phase III Trial PROUD-PV

Ropeginterferon alfa 2b is a novel, long-acting, mono-pegylated Interferon, administered only once every 14 days, after achieving therapy response even only monthly. Based on previous Phase I/II trials, Ropeginterferon alfa 2b is expected to be safe and effective in the majority of PV patients. Haematological and molecular responses occured in most patients; moreover, several patients achieved undetectable mutated JAK2 levels and a complete normalisation of their chromosomal make-up.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Practical therapeutics Industry News Haematology Oncology Patient care JAK2 Latest News myeloproliferative neoplasms Polycythemia Vera PROUD-PV Ropeginterferon alfa 2b Source Type: news